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ABSTRACT:
Genetic and epigenetic events within a cell which promote a block in normal 
development or differentiation coupled with unregulated proliferation are hallmarks 
of neoplastic transformation. Differentiation therapy involves the use of agents with 
the ability to induce differentiation in cells that have lost this ability, i.e. cancer 
cells. The promise of differentiation-based therapy as a viable treatment modality 
is perhaps best characterized by the addition of retinoids in the treatment of acute 
promyelocytic leukemia (APML) revolutionizing the management of APML and 
dramatically improving survival. However, interest and application of differentiation-
based therapy for the treatment of solid malignancies have lagged due to deficiencies 
in our understanding of differentiation pathways in solid malignancies. Over the past 
decade, a differentiation-based developmental model for solid tumors has emerged 
providing insights into the biology of various solid tumors as well as identification 
of targetable pathways capable of re-activating blocked terminal differentiation 
programs. Furthermore, a variety of agents including retinoids, histone deacetylase 
inhibitors (HDACI), PPARγ agonists, and others, currently in use for a variety of 
malignancies, have been shown to induce differentiation in solid tumors. Herein we 
discuss the relevancy of differentiation-based therapies in solid tumors, using soft 
tissue sarcomas (STS) as a biologic and clinical model, and review the preclinical data 
to support its role as a promising modality of therapy for the treatment of solid tumors.
INTRODUCTION
Differentiation therapy is a therapeutic modality 
aimed at re-activating endogenous differentiation 
programs in cancer cells with subsequent tumor cellular 
maturation and concurrent loss of the tumor phenotype. In 
modern literature, one can trace the conceptual origins of 
differentiation therapy to the work of G. Barry Pierce who 
posited that malignant cells could differentiate into non-
malignant cells [1, 2]. Although a theoretically attractive 
option, differentiation therapy has historically been greatly 
hampered by both our practical lack of understanding of 
the biology of normal differentiation pathways as well as 
by our theoretical inability to envision a methodology that 
could restore or supersede a tumor’s immutable genetic 
level mutations which result in the lineage specific block 
to differentiation and subsequent tumorigenesis. Another 
long standing drawback of differentiation therapy has been 
its practical and theoretical disadvantage as compared 
to novel and even conventional cytotoxic approaches. 
Cytotoxic chemotherapy aims directly at cancer cell death 
while differentiation therapy alludes to a more complex 
and more nebulous process of cancer to normal tissue 
transitioning. 
However, if there is one thing we have learned 
over the last 50 years of treating cancer patients, it is that 
conventional approaches (e.g., conventional cytotoxic 
agents, targeted antibodies or small molecule inhibitors) 
are  not  sufficient  in  effecting  cures  for  a  significant 
proportion of cancer patients. According to the American 
Cancer Society register, this year more than 500,000 
Americans will die of cancer accounting for nearly 1 of 
every 4 deaths [3]. And, while the 5-year survival rate for 
all patients diagnosed with cancer in the last ten years is Oncotarget 2012; 3:  559-567 560 www.impactjournals.com/oncotarget
66%, up from the 50% rate of the 1970s [3], that means, 
as of today, one out of every three patients diagnosed with 
cancer will not be alive five years later. Clearly there is 
reason to pursue all potential therapeutic options.
However, is differentiation therapy a “realistic” 
potential therapeutic option? Is it really possible to 
make cancer – “normal”? In the era before retinoic acid-
based differentiation therapy for acute promyelocytic 
leukemia (APML), through the use of various cytotoxic 
chemotherapies the remission rates had progressively 
improved from 50 to 80%, of which only about 35% could 
expect to be long term survivals. However, now with the 
use of retinoic acid and chemotherapy more than 90% of 
patients with newly diagnosed APML patients can achieve 
complete remission and about 75% can be cured [4-13]. 
Mechanistically, APML cells in the vast majority of 
patients have a characteristic chromosomal translocation 
t(15;17) that produces the fusion gene consisting of the 
promyelocytic leukemia (PML) and retinoic acid receptor 
α (RARα) genes. PML-RARα retains critical domains of 
PML and RARα, and plays a key role in the pathogenesis 
of APML by recruiting transcriptional repressors, histone 
deacetylases (HDACs), and DNA methyltransferases. 
Pharmacological doses of ATRA trigger dissociation of 
PML-RARα/HDAC complexes resulting in degradation 
of PML-RARα and resumption of myeloid differentiation 
in APML cells [14]. Explained in the above manner – the 
use of retinoic acid to “relieve” the differentiation block 
makes complete sense. 
So why aren’t there more examples of differentiation 
therapy? For hematopoietic malignancies it has been 
argued that APML represents an isolated example of a 
“simple karyotype” disease that is both addicted to the 
characteristic fusion gene for tumorigenicity and has 
minimal other genetic abnormalities. Thus, the reversal 
of one pathway is sufficient to reverse the tumorigenicity 
of APML and place it back on the road to normal 
differentiation, something that is unlikely to be true for 
other hematopoietic malignancies. For solid tumors, the 
application of differentiation therapy has been further 
compounded by the absence of developmental models 
of cancer progression that correlate cancer subtypes to 
stages of normal development. Models such as those 
proposed by Pierce and colleagues have been historically 
minimized in favor of the more common notions of solid 
tumorigenesis which hypothesize that mutations occurring 
in “normal” tissue results in gradual dedifferentiation to 
cancer cells harboring features of normal tissue reflecting 
varying degrees of differentiation – a feature invariably 
linked to cancer aggressiveness [15]. Therefore, even the 
consideration of differentiation-based therapy in solid 
tumors has been hampered by the lack of developmental-
based classifications of solid tumors. 
In this review, we discuss how recent advances in 
the developmental-based classification of solid tumors are 
paving the way and leading to novel differentiation-based 
therapies for solid tumors.
Differentiation-based  classification  models  of 
cancer
Similar to other solid tumors, sarcomas have been 
historically classified based on histopathological features 
reflecting  the  degree  to  which  these  tumors  resemble 
normal tissue. However, unlike other solid tumors, the 
existence of a connective tissue (mesenchymal) stem cell, 
along with in vitro methodologies to differentiate them into 
mature tissues, have allowed us, for the first time, to query 
whether sarcoma subtypes arise as a result of cellular 
transformation at discrete stages of differentiation [16]. 
Through gene clustering and distance correlation analyses, 
our group was able to correlate the expression signatures 
of each liposarcoma subtype to a corresponding point 
along the adipocytic differentiation time course providing 
evidence that the dedifferentiated and pleomorphic 
liposarcoma subtypes represent cells arrested at an early 
point in differentiation compared to myxoid/round-cell 
and well-differentiated cells which arrest at later and 
more mature stages of development. Furthermore, our 
analysis of differentially expressed genes identified genes 
marking discrete stages of adipocytic differentiation 
and discriminating these genes from markers that may 
be involved in malignant transformation and potentially 
amenable to therapeutic targeting. Picking up on this 
theme, and using significantly advanced computational 
methodologies, Riester and colleagues recently developed 
a statistical algorithm utilizing gene expression data from 
different cancers (including AML, breast carcinoma 
and liposarcoma) to construct phylogenetic trees which 
objectively and systematically categorized cancer 
subtypes based on degrees of maturation and relative 
to their corresponding cells of origin (e.g. hMSC for 
liposarcomas) [17]. The algorithm proposed successfully 
classified: (1) the AML subtypes in accord with the FAB 
classification schema (e.g. M0 subtype was arrayed closest 
to stem cells); (2) breast carcinoma based on estrogen 
receptor (ER) status; and (3) confirmed our initial findings 
in liposarcomas as described above. This developmental-
based approach represents not only a new method for 
reclassifying solid tumors, but also provides fundamental 
insight into solid tumor etiology.
Targeting of differentiation pathways
Along  with  the  changing  classification  systems 
that now plot solid tumors onto developmental maps, 
we are getting better at understanding how to activate 
differentiation pathways in cancers so as to progress 
them along their developmental paths. Using this 
rationale, we have previously shown that mesenchymal 
stem cells (MSCs) are the progenitors of malignant Oncotarget 2012; 3:  559-567 561 www.impactjournals.com/oncotarget
fibrous  histiocytoma  (MFH;  now  termed  high  grade 
undifferentiated pleomorphic sarcoma [HGUPS], a 
commonly diagnosed mesenchymal tumor) and that 
increased levels of DKK1, a Wnt developmental pathway 
inhibitor, mediate the transition from the MSC state to 
the MFH state [18]. Perhaps, more importantly, we have 
been able to demonstrate that MFH cells in which Wnt 
signaling is re-established to mirror the MSC-state become 
amenable to differentiation into mature connective tissue 
lineages with concurrent loss of tumor cell properties [18]. 
Although a novel finding at the time, if one looks closely 
enough, there are many agents already in clinical practice 
that may function as differentiation agents.
Histone deacetylase inhibitors
Epigenetic modifications which affect the chromatin 
architecture have been implicated in malignant progression 
and transformation [19]. Histone deacetylation, mediated 
by histone deacetylases (HDACs), leading to chromatin 
compaction is associated with transcriptional repression of 
tumor suppressors involved in regulating cell growth and 
differentiation in different cancers including sarcomas [20, 
21]. Hence, there has been considerable interest in HDAC 
inhibitors (HDACIs) and preclinical data to suggest a 
differentiation indcuing effect of HDACIs in a variety of 
solid tumor and sarcoma models [22-26].
Platta and colleagues showed that a small 
cell lung carcinoma cell line, DMS53, underwent 
dramatic morphological changes suggestive of cellular 
differentiation following treatment with the histone 
deacetylase inihibitor (HDACI), trichostatin A [27]. 
Rephaeli and colleagues showed that treatment of mice 
with  established  22Rv1  prostate  tumors  with  AN-7, 
a prodrug of butyric acid, resulted in AN-7-treated 
tumors being uniformly positive for PSA -indicative 
of differentiation [28]. Martirosyan and colleagues 
showed that five quinoline compounds based compounds 
inhibited HDAC activity in vitro and stimulated cell 
differentiation at growth inhibitory concentrations in 
MCF-7 breast carcinoma cells in vitro [29]. Munster 
and colleagues showed that treatment  with SAHA 
(suberoylanilide  hydroxamic acid or vorinostat), 
resulted  in  significant  changes  in  the  morphology  of 
MCF-7 breast carcinoma cells suggestive of epithelial 
mammary differentiation [30]. Sakimura and colleagues 
[31] observed that intraperitoneal administration 
of depsipeptide to chondrosarcomas xenografted in 
nude mice resulted in down-regulated the synthesis 
of glycosaminoglycans and an elevation of alkaline 
phosphatase activity; both consistent with chondrosarcoma 
differentiation.
Retinoids
Retinoids are a class of compounds derived from 
vitamin A that have demonstrated the ability to regulate 
cell proliferation, differentiation and apoptosis in normal 
and cancer cells [32]. Retinoids are believed to exert their 
effects by binding to retinoic acid receptors (RARs) that 
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Figure 1: Schematic representation and suggested terminology for different ways in which cancer may be differentiatied.Oncotarget 2012; 3:  559-567 562 www.impactjournals.com/oncotarget
exist as 3 isoforms (RAR-α/- ß /-γ). 
Treatment of osteosarcoma and chondrosarcoma 
cell lines with ATRA have resulted in reversible growth 
inhibition and a decrease in colony formation [33, 34]. 
Further in vitro studies have showed that retinoic acid 
treatment  results  in  hypophosphorylation  of  RARα 
inhibiting cellular proliferation and inducing osteoblastic 
differentiation which may provide a potential mechanism 
to explain the clinical effects observed [35]. A similar anti-
proliferation and pro-differentiation effect has also been 
described  for  rhabdomyosarcoma  (RMS)  treated  with 
retinoids. Use of retinoids in a variety of RMS cell lines 
derived from either alveolar or embryonal RMS displayed 
a reduction of cell proliferation along with a concomitant 
induction of myogenic differentiation [36-39]. Knockdown 
of  XAB2,  believed  to  be  a  component  of  the  RAR 
corepressor complex, is able to increase ATRA-induced 
differentiation in RMS, APML and an ATRA-resistant 
neuroblastoma cell lines. Xenografted cells did exhibit 
a reduction of proliferation and morphologic evidence 
of muscle differentiation following ATRA treatment in 
vitro. Levels of the cyclin-dependent kinase inhibitors 
(CDKIs) p18, p21 and p27 were shown to be increased 
in all treated RMS cell lines but no CDK4 inhibition or 
hypophosphorylation of the Rb protein suggesting that 
ATRA-induced differentiation was not sufficient to induce 
cell cycle arrest in RMS cells. However, it is important to 
note that although ATRA did not reduce the time to relapse, 
the tumors obtained from ATRA-treated mice showed 
evidence of enhanced muscle differentiation (increased 
expression of the terminal muscle differentiation marker 
myosin heavy chain). Despite the variable outcomes 
following retinoid treatment of sarcoma cells, there 
continues to be a significant body of research to support 
further investigations into the anti-tumorigenic effects of 
retinoid-based differentiation of sarcomas, particularly for 
osteosarcoma and rhabdomyosarcoma. 
PPARγ Agonists
Peroxisome  proliferator-activated  receptor  -  γ 
(PPARγ) has been shown to be an important regulator of 
cell proliferation, differentiation and apoptosis in a variety 
of cell types including hepatocytes, fibroblasts, myoblasts 
and adipocytes [40, 41]. The biological effects of PPARγ 
have been found to be related to cell type and the specific 
ligand binding to PPARγ. Endogenous ligands of PPARγ 
include several unsaturated fatty acids and metabolites of 
arachidonic acid such as 15-deoxy-Δ 12,14-prostagladin 
J2 (15d-PGJ2). Synthetic ligands of PPARγ have been 
developed and include the thiazolidinediones (e.g. 
troglitazone, rosiglitazone), oral agents used in the 
management of type 2 diabetes mellitus, and non-steroidal 
anti-inflammatory drugs (NSAIDs; e.g. indomethacin). 
Morrison and Farmer demonstrated that treatment of 
3T3-L1 preadipocytes and murine fibroblast cell lines with 
the PPARγ agonist troglitazone resulted in the induction of 
the cyclin-dependent kinase inhibitors (CDKIs) p18 and 
p21 allowing for withdrawal of cells from the cell cycle 
and initiation of terminal adipogenic differentiation [42]. 
Development of knockout mouse models of PPARγ have 
revealed its importance in the development of adipose, 
placental and cardiac tissue as the null-PPARγ phenotype 
is embryonic lethal [43]. Activation of PPARγ with either 
endogenous PPARγ agonists (e.g. 15d-PGJ2) or synthetic 
agonists  (e.g.  RSG)  have  been  effective  in  inducing 
cell cycle exit followed by terminal differentiation of 
preadipocytes  and  fibroblast  cells  implicating  PPARγ 
activation in the regulation of lipid homeostasis [42, 44, 
45]. 
Cellular differentiation has also been observed 
in cancer cell lines. Elstner and colleagues treated 
the  breast  cancer  cell  line  MCF7  with  the  PPARγ 
agonist troglitazone (TGZ) and observed the inhibition 
of proliferation along with lipid accumulation. The 
combination of TGZ with the RXR agonist, ATRA, had a 
synergistic effect in irreversibly inhibiting MCF7 growth, 
reduction of BCL2 expression, and apoptosis of cells [46]. 
Relatedly, Sarraf and colleagues treated colon carcinoma 
cells with TGZ and demonstrated an increase in the 
levels of carcinoembryonic antigen (CEA), a marker of 
differentiation in colon carcinoma cell lines [47]. Perhaps 
one of the more pronounced effects of PPARγ activation 
is seen with PPARγ agonist treatment of liposarcoma. 
Tontonoz and colleagues were able to show that primary 
human liposarcoma (LPS) cells were effectively induced 
to undergo terminal adipocytic differentiation following 
treatment  with  the  PPARγ  agonist,  pioglitazone  [48]. 
Furthermore, they demonstrated additive effects in 
inducing adipocytic differentiation when LPS cells were 
treated with a combination of pioglitazone and an RXRα-
specific  ligand,  LG268.  These  promising  preclinical 
results  regarding  the  differentiative  effects  of  PPARγ 
agonist treatment in liposarcoma have been subsequently 
pursued in a clinical phase II trial utilizing the PPARγ 
agonist rosiglitazone [49].
Trabectedin
Trabectedin (ecteinascidin-743 or ET-743; Yondelis) 
is a compound derived from the Caribbean tunicate 
Ecteinascidia turbinata and was discovered to have 
anti-tumor activity in the early 1970s through a survey 
of pharmacologic activity in plant- and marine-derived 
materials sponsored by the National Cancer Institute [50]. 
Binding of trabectedin to the DNA minor groove at the N2 
position of guanine is believed to result in conformational 
changes of the DNA double helix disrupting the binding 
of transcription factors and potentially underlying its 
anti-tumor effects in select cancers [51-54]. Forni and 
colleagues evaluated the effects of trabectedin treatment 
in myxoid liposarcoma cell lines and found that Oncotarget 2012; 3:  559-567 563 www.impactjournals.com/oncotarget
trabectedin induces the dissociation of TLS-CHOP from 
target promoter sequences based on a series of chromatin 
immunoprecipitation  experiments  [55].  RT-PCR  and 
Western immunoblot analyses of TLS-CHOP revealed 
stable expression levels suggesting that trabectedin 
does not result in the downregulation of TLS-CHOP 
expression. The dissociation of TLS-CHOP from target 
promoters results in the downregulation of TLS-CHOP 
target genes (e.g. CHOP, PTX3, FN1), but consequently 
induces an adipogenic differentiation program involving 
re-expression of the CAAT/enhancer binding protein (C/
EBP) transcription factor family of genes which play key 
roles in regulating adipogenic differentiation. In MLS, 
TLS-CHOP is believed to sequester C/EBPß preventing 
binding to its promoter and blocking progression of the 
adipogenic differentiation program. Trabectedin disrupts 
the association of TLS-CHOP and C/EBPß allowing C/
EBPß activation of C/EBPα resulting in the initiation 
of terminal adipogenic differentiation. The novel 
mechanism of action of trabectedin coupled with its 
demonstrated efficacy in preclinical models either singly 
or in combination with converntional chemotherapy drugs 
makes it a promising candidate for continued investigation 
in formal clinical trials of patients with soft tissue sarcoma. 
Differentiation-based therapy in patients.
To this point it could be argued that the differentiation 
effects described have been limited to cell lines and/or 
observed primarily under in vitro conditions. However, we 
would contend that differentiation as an in vivo or even a 
clinical end point has never been primarily sought out and 
thus rarely examined. We now provide clinical examples 
to support the preclinical data cited above. 
NCI6338 evaluated the HDACI depsipeptide in 
patients with progressive recurrent and/or metastatic non-
medullary  radioactive  iodine  (RAI)-refractory  thyroid 
cancer. This trial also evaluated the ability of depsipeptide 
to promote differentiation via assessment of increased RAI 
avidity in these tumors. Importantly, in a proof of principle 
event, clinically observed differentiation of thyroid tumor 
cells was observed with significant restoration of RAI 
avidity in two patients [56].
Demetri and colleagues conducted a small clinical 
trial of the PPARγ agonist troglitazone (TGZ) in patients 
with liposarcoma [57]. Serial biopsy results on 3 patients 
treated with TGZ revealed histologic changes consistent 
with increased lipid accumulation in tumor biopsy samples 
as well as marked increases in tumor triglycerides and 
phosphatidylcholine levels, and decreases in Ki-67 cell 
proliferation marker expression. Interestingly, the degree 
of adipocytic differentiation based on tumor triglyceride 
levels induced by TGZ treatment was most pronounced 
in  a  patient  with  the  myxoid/round  cell  LPS  variant. 
Furthermore, increases in fat density signal based on 
serial MRI examination of one patient with pleomorphic 
LPS was observed. However, such responses could not be 
validated in a subsequent trial [49]. 
In our own clinical experience we have observed 
the potent and rapid adipogenic differentiation effects 
of trabectedin on one patient with a myxoid round cell 
liposarcoma (MRCLS) [54] confirming previous reports 
of such rare differentiation-based responses in this 
sarcoma sub-type to trabectedin treatment [58]. As we 
have recently reported, a heavily pre-treated and locally 
recurrent large MRCLS (i.e., tumor displacement of the 
diaphragm and liver with complete extention into the 
pelvis) underwent a significant change in density from 
soft-tissue to fat corresponding to a 10 kg weight loss 
following several cycles of single-agent trabectedin. The 
patient also exhibited significant clinical improvement, 
but without radiological evidence of changes in tumor size 
measurements (i.e., stable disease as defined by RECIST 
criteria) [54]. The patient, whose disease was rapidly 
progressing at the time of trabectedin treatment, lived 
another two years without the need for surgical resection. 
At the time of our publication [54], he had begun to 
progress with areas of high grade sarcoma reasserting 
itself in the areas of well-differentiated fat. However, we 
are happy to report that he recently underwent aggressive 
surgical resection which removed a 55 pound mostly 
well-differentiated tumor/fat mass. Thus, review of the 
available literature on the potential of trabectedin and 
PPARγ agonists coupled with case reports on the efficacy 
of these agents in solid tumors highlights the relevancy 
and future promise of differentiation-based therapy as a 
novel treatment strategy for sarcoma patients warranting 
further investigation.
Elucidating the mechanisms behind rare clinical 
observations
It is easy to relegate the above examples of clinical 
solid tumor differentiation therapy as anectodes and/or 
“fascinomas” of clinical medicine. In our own experience 
only one of 7 patients with MRCLS responded in such 
a manner to trabectedin. One could then ask, “Why?” 
If trabectedin works (as described above) via the 
reversal of TLS-CHOP-mediated sequestration of pro-
adipogenic transcription factors resulting in re-initiation 
of the adipogenic program, why did only one of 7 patients 
experience the differentiation effect? Our recent work 
identified that this patient had one specific sub-type of 
TLS-CHOP (type II) and that this was also the only patient 
who possessed a mutated form of p53 [54]. Knowing 
this, we were able to generate an MRCLS mouse model 
that not only recapitulated MRCLS histopathology, but 
also its differentiation-based response to trabectedin. 
Perhaps more importantly we were able to use this 
model to demonstrate two important points: (a) ET-743 
(trabectedin) downregulates TLS-CHOP expression post-Oncotarget 2012; 3:  559-567 564 www.impactjournals.com/oncotarget
transcriptionally; and (b) once adipocytic differentiation 
has been re-initiated via the actions of trabectedin, PPARγ 
agonists can then accelerate the differentiation process. 
We propose that once the biology of a cancer is better 
understood, differentiation therapy loses its mysticism. In 
short, as we, as a scientific-medical community, uncover 
both the developmental origins of cancer as well as 
the differentiation pathways that promote the normal 
maturation of cells, the re-institution of the latter (i.e., 
normal differentiation) into the former (i.e., cancer cells) 
will become more and more routine. As a result, we will 
undoubtedly look back at these days of one-fit-for-all 
cytotoxic chemotherapies as not only overly simplistic but 
literally, not just figuratively, off-target.
Going forward with differentiation therapy
In this review, we have provided pre-clinical, clinical 
and mechanistic evidence for solid tumor differentiation 
therapy. But to imply that all differentiation therapy is 
going to be the same would be to simplify what is likely 
an extremely complicated phenomenon. We now present 
three ways in which cancer differentiation therapy 
can  theoretically  occur  (Figure  1):  1)  cancer  directed 
differentiation; 2) cancer reverted differentiation; and 
3) cancer diverted differentiation. In cancer directed 
differentiation, differentiation pathways are activated 
without correcting the underlying oncogenic mechanisms 
that have resulted in the initial differentiation block. 
In cancer reverted differentiation, correction of the 
underlying oncogenic mechanism results in natural 
restoration of endogenous differentiation pathways. 
Lastly, in cancer diverted differentiation, the cancer cell 
is redirected to an earlier stage of differentiation where 
access to alternative differentiation routes may be feasible. 
Thus, the cancer cell may then differentiate along an 
alternative lineage towards one in which its differentiation 
was not blocked. 
Although it is tempting to ascribe the previously 
presented examples of differentiation therapy to the 
various mechanistic models of differentiation therapy just 
described, we will not do so here as such an assignment 
would imply that we completely understand the means 
in which differentiation is achieved in these cancer cells. 
Finally, we believe that there is great plasticity to these 
processes and differentiation therapy is likely to follow a 
spectrum of possibilities that may ultimately, at best, be 
only approximated by the models described above.
The general end point for cancer therapeutics has 
revolved around the idea of a complete eradication of 
cancer cells. Although adoption of a differentiation-based 
approach to this tenet of medical therapy may seem like 
a consolation, the potential for reversion of the malignant 
cancer phenotype to a more benign, or at the very least 
a lower grade of biologic aggressiveness, may serve as 
a critical clinical and biologic transition of a uniformly 
fatal cancer into one more amenable to management or to 
treatment using conventional therapeutic approaches. For 
differentiation therapy to be successful, it does not need 
to eliminate all the cancer cells or even differentiate them 
all to “normal” mature cells. If successful, the change in 
pathological status alone (e.g., from high grade to low 
grade or poorly to well differentiated), accomplished using 
differentiation therapy, will change the prognosis of most 
patients with cancer by decades. 
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